Purpose: Epstein-Barr virus-positive (EBV þ ) diffuse large B-cell lymphoma (DLBCL) of the elderly is a variant of DLBCL with worse outcome that occurs most often in East-Asian countries and is uncommon in the Western hemisphere. We studied the largest cohort of EBV þ DLBCL, independent of age, treated with rituximab combined with CHOP (R-CHOP) in developed Western countries. Experimental design: A large cohort (n ¼ 732) of patients with DLBCL treated with R-CHOP chemotherapy is included from the multicenter consortium. This study group has been studied for expression of different biomarkers by immunohistochemistry, genetic abnormalities by FISH and mutation analysis, genomic information by gene expression profiling (GEP), and gene set enrichment analysis (GSEA).
for EBV positivity. The lack of consensus may impact differences in the reported prevalence. Lymph nodes are commonly involved ($70%), and extranodal sites of involvement are not uncommon (3) . Although prognostic significance has not been demonstrated, two morphologic variants, monomorphic and polymorphic, have been recognized. Recently, Montes-Moreno and colleagues subdivided the polymorphic subtype based on the relative proportion of large neoplastic cells and the presence of Hodgkin Reed-Sternberg-like cells into three groups: (i) canonical large B-cell neoplasm, (ii) DLBCL with Hodgkin lymphoma-like features, and (iii) DLBCL with polymorphic lymphoproliferative disorder-like features (9) . Immunophenotypically, most cases have activated Bcell phenotype. EBV latent membrane protein 1 (LMP1) is expressed in more than 90% of cases, which denotes EBV latency type II. EBV nuclear antigen 2 (EBNA2), seen in EBV latency type III, is expressed in approximately 15% to 30% of cases. Specific cytogenetic and genomic aberrations are not known.
In reports from East Asia, South America, and Europe, a poor outcome has been observed in patients with EBV þ DLBCL of the elderly (5, 8, 10, 11) . In these studies, however, many patients were treated with cyclophosphamide, hydroxydoxorubicin, vincristine, and prednisone (CHOP) and not rituximab (R)-CHOP. Therefore, the effect of R-CHOP immunochemotherapy in patients with EBV þ DLBCL of the elderly is largely unknown. In this study, we assessed the effect of EBV infection in a large cohort of patients with DLBCL treated with R-CHOP in Western developed countries.
Materials and Methods

Patients
A total of 732 cases (training set, n ¼ 500 and validation set, n ¼ 232) of de novo DLBCL treated with R-CHOP were evaluated. Formalin-fixed and paraffin-embedded lymphoma samples were a part of the International DLBCL Rituximab-CHOP Consortium Program Study. All cases were reviewed by a group of hematopathologists (A. Tzankov, M.B. Mller, M.A. Piris, and K.H. Young) and were diagnosed according to the WHO criteria. DLBCLs transformed from a low-grade B-cell lymphoma or associated with acquired immunodeficiency (e.g., HIV infection), primary cutaneous DLBCLs, primary central nervous system DLBCLs, and primary mediastinal large B-cell lymphomas were excluded. We did not exclude patients younger than 50 years. Morphologic variants of EBV þ DLBCL were classified as described by
Montes-Moreno and colleagues (9) . This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Boards (IRB) of all participating collaborative institutions (12, 13) . The overall study was approved by the IRB at The University of Texas MD Anderson Cancer Center (Houston, TX).
Immunohistochemistry and in situ hybridization methods Tissue microarrays (TMAs) were constructed as described previously (12, 13) . Immunohistochemical analysis (IHC) for various markers and in situ hybridization (ISH) for EBVencoded RNA (EBER) were performed. Evaluated IHC markers were B-cell lymphoma 2 (BCL2), B-cell lymphoma 6 (BCL6), CD10, CD30, forkhead box protein P1 (FOXP1), germinal center B cell-expressed transcript-1 (GCET1), E3 ubiquitin-protein ligase Mdm2 (MDM2), protein Mdm4 (MDM4), multiple myeloma oncogene 1 (MUM1), EBV latent membrane protein 1 (LMP1, ThermoFisher Scientific, Rockford, IL), EBV nuclear antigen 2 (EBNA2, Abcam, Cambridge, MA), Myc, NF-kB components (p50, p52, p65, RelB, and c-Rel), p53, and phosphorylated STAT3 (pSTAT3). Receiver-operating characteristic (ROC) curve analysis, described previously (14) , was utilized to assess a cutoff with maximum sensitivity and specificity for each marker. When an optimal cutoff could not be determined by ROC curve analysis, a conventional cutoff value for individual markers was decided on the basis of a literature review. The cutoff scores for these markers were as follows: 10% for LMP1, MDM2, MDM4, and EBER; 20% for CD30 and p53; 30% for CD10, BCL6, and pSTAT3; 40% for Myc; 60% for GCET1, MUM1, and FOXP1; and 70% for BCL2. Any nuclear expression of each NF-kB component was considered positive.
Gene expression profiling and gene set enrichment analysis
Total RNA was extracted from 474 formalin-fixed, paraffin-embedded tissue samples in the training set using the
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High Pure RNA Extraction Kit (Roche Applied Science) and subjected to gene expression profiling (GEP) as described previously (14) . We used the DQN algorithm, which is the noncentral trimmed mean of differences between perfect match and mismatch intensities with quantile normalization, for data analysis and classification (15) . DQN was normalized with beta distribution and a Bayesian model was used to determine the classification probability. The methodology developed in this study has been validated with the Lymphoma Leukemia Molecular Profiling Program dataset in the Gene Expression Omnibus Genomics Spatial Event database #10846, which has 181 CHOPtreated and 233 R-CHOP-treated patients with DLBCL. We obtained an 80% concordance rate of classification for all three classes, germinal center B-cell (GCB), activated B-cell (ABC), and unclassified, and a 97% rate for GCB and ABC (excluding unclassified). Cell-of-origin (COO) classification was established by GEP (considered the "gold standard") and/or in combination with IHC data. When COO is not classifiable with GEP, it was determined by IHC according to Visco-Young (the first choice) and Choi (the second choice) algorithms (14, 16) . The correlation between GEP and IHC for COO classification was 86.3% overall (17) . Gene set enrichment analysis (GSEA) was performed with GSEA application (Broad Institute at MIT, Cambridge, MA) using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway gene sets and the curated gene sets from the Molecular Signature Database. Gene sets with a false discovery rate q value <0.05 after performing 1,000 permutations were considered to be significantly enriched.
FISH for BCL2, BCL6, MYC, MDM2, and MDM4 and sequencing of TP53
FISH analysis was performed on formalin-fixed, paraffinembedded tissue sections using BCL2 and BCL6 dual-color break-apart probes (Vysis), MYC locus-specific IGH/MYC/ CEP8 tricolor dual-fusion probes, and a locus-specific MYC dual-color break-apart probe (Vysis), and MDM2 and MDM4 probes as described previously (12, 14) . TP53 sequencing was performed using extracted genomic DNA from formalinfixed, paraffin-embedded tissue in the training set. The coding sequence (exons 2-11) and splicing sites were sequenced using p53 AmpliChip (Roche Molecular Systems) as described in ref. (13) . Sequence data were compared with the TP53 reference sequence (NC_000017.10) in the Genbank database for data analysis.
Statistical analysis
Clinical and laboratory features were compared with the Fisher exact test for categorical variables and Mann-Whitney U test for continuous variables. Overall survival (OS) and progression-free survival (PFS) were defined from the date of diagnosis to the date of last follow-up or death and from the date of diagnosis to the date of progression or death, respectively. Survival distributions were estimated with the Kaplan-Meier method, with difference compared by the log-rank test. Multivariate analysis was performed using the Cox proportional hazards regression model. All differences with P < 0.05 were considered to be statistically significant. SPSS Statistics V21.0 was used for statistical analyses. Fig. S1 ) according to Montes-Moreno's subclassification scheme (9) . There was no significant difference in OS and PFS among different morphologic variants (P ¼ 0.915 and P ¼ 0.931, respectively). Eleven cases were GCB and 17 cases were ABC subtype. With a median follow-up of 42.1 months, patients with EBV þ DLBCL did not show any significant differences from patients with EBV-negative (EBV À ) DLBCL with respect to OS and PFS in the training set (P ¼ 0.189 and P ¼ 0.687, respectively; Fig. 1A and B). This finding was reproduced in the validation set (P ¼ 0.849; Fig. 1C ) and in the combined set (P ¼ 0.192; Fig. 1D ). Information on PFS was not available in the validation set. Combining the training and validation sets, the 5-year OS was 54% for patients with EBV þ DLBCL compared with 64% for patients with EBV À DLBCL (P ¼ 0.321). The 5-year PFS was 57% and 58% in these groups, respectively (P ¼ 0.867 Table 3) .
Results
Clinicopathologic
Expression of NF-kB components and phosphorylated
Components of NF-kB (p50, p65, and c-Rel) and pSTAT3 were assessed by IHC. Expression of p50 was more commonly observed in EBV þ DLBCLs compared with EBV À DLBCLs (65.2% vs. 35.9%, P ¼ 0.007). In contrast, expression of p65 and c-Rel showed no difference between the two groups. These findings could suggest that the canonical NFkB pathway is activated using both p65 and c-Rel as dimerization partners for p50. Of note, nuclear expression of canonical NF-kB molecules was also expressed in GCB subtype of EBV þ DLBCLs (55.6%, 54.8%, and 33.3% for p50, p65, and c-Rel, respectively), suggesting EBV-associated canonical NF-kB induction. However, single LMP1 or EBNA2 did not show significant correlation with any of the NF-kB molecules (all P > 0.05). pSTAT3 was more commonly expressed in EBV þ DLBCLs compared with EBV À DLBCLs (56.5% vs. 34.9%, P ¼ 0.044). However, pSTAT3 did not show significant correlation with LMP1 (P > 0.05).
CD30 expression predicts adverse outcome in patients with EBV þ DLBCL Our group previously found that coexpression of CD30 and EBER in de novo DLBCLs harbors poor prognosis (12 Gene expression signature and GSEA of EBV þ DLBCL
We evaluated GEP signatures of EBV þ and EBV À DLBCL to better understand molecular mechanisms involved in EBV þ DLBCL (Fig. 3A) . A total of 24 genes were differentially expressed between the two groups. In EBV þ DLBCL, seven genes were upregulated and 17 genes were downregulated (Supplementary Table S1 ). Among the upregulated genes, FTH1, PDXK, MRPL44, P4HB, and ENTPD6 were noteworthy. FTH1 is a known NF-kB target gene that denotes an activated NF-kB pathway. PDXK is positively related to cell proliferation. MRPL44 involves cell-cycle regulation and P4HB and ENTPD6 are involved in cell metabolism. Among the downregulated genes, MIR17HG, MOCOS, and EYA4 were prominent. Downregulation of MIR17HG has been shown in CD30 þ DLBCL by Hu and colleagues (12), and our finding underscores an association between CD30 expression and EBV infection. MOCOS sulfurates the clincancerres.aacrjournals.org Downloaded from molybdenum cofactor, essential for the enzyme activity of aldehyde oxidase. Because aldehyde oxidase is a major enzyme involved in drug metabolism and clearance, downregulation of MOCOS could be a possible mechanism of chemotherapeutic resistance (18) . EYA4 is a gene involved in DNA repair and EYA4 downregulation has been associated with poor clinical outcome in patients with nonHodgkin lymphoma (19) .
We further conducted GEP in EBER þ /CD30 þ DLBCL and
A total of 68 genes were differentially expressed between the two groups (Fig. 3B) . Among 44 upregulated genes in EBER þ /CD30 þ DLBCL, NME5 has an antiapoptotic effect, C10orf46 promotes cell proliferation, and ZC4H2 induces cell-cycle progression. Among 14 genes downregulated in EBER þ /CD30 þ DLBCL, RSF1, PTPN6, and OSBP were conspicuous. Downregulation of RSF1, which normally represses the NF-kB pathway, might contribute to NF-kB activation. PTPN6 and OSBP normally dephosphorylate substrates, and downregulation of these genes could enhance a variety of signal transduction pathways.
We used KEGG gene sets for GSEA. The Toll-like receptor and RIG-1-like receptor signaling pathways were significantly enriched in EBV þ DLBCL (Fig. 3C ). These pathways can activate the NF-kB pathway, providing indirect evidence of enhanced NF-kB activity in EBV þ DLBCL. The GSEA also demonstrated enrichment of the JAK/STAT signaling pathway, compatible with enhanced expression of pSTAT3 in EBV þ DLBCL (Fig. 3D ). This finding suggests that STAT3 might be activated by EBV, similar to STAT3 activation by LMP1 in nasopharyngeal carcinoma (20) .
Discussion
In a cohort of 732 patients with de novo DLBCL treated with R-CHOP, the prevalence of EBV was 4.0%. A prior report from Korea showed that EBER expression (cutoff !20%) was associated with >60 years, advanced Ann Arbor stage, !2 extranodal site involvement, high intermediate/high international prognostic index, and B symptoms (5 novo DLBCL and our study group is composed of Caucasian patients, the difference between prior data and ours might be related to different characteristics of host factors and ethnic background. For example, polymorphisms in chemokine or cytokines such as CCR5-D32, CCR2-64I, SDF1-3 0 A, IL4-589T, and IL10-5 0 592A are observed with different frequency between European Caucasians and East Asians (21) (22) (23) . In addition, different allele frequency in HLA molecules might explain the different clinical manifestations in EBV þ DLBCL compared with Asian patients. Interestingly, one study showed that CCR5-D32 polymorphism, which is found in 5% to 15% of Caucasians but not seen in Asians, reduced the risk of DLBCL and follicular lymphoma in Caucasian men, partly explaining the different prevalence of EBV þ DLBCL in developed Western countries (24) . Similar to the host factors, geographic variation of EBV strains might also contribute to the different prevalence and clinical behavior of EBV þ DLBCL. Frequency of type I and type II EBV, based on genetic polymorphisms in EBNA2 and EBNA3 genes, is different according to geographic region (25) . Genome sequencing of three different EBV strains (B95-8, GD1, and AG876) showed that LMP1 sequence in GD1 (in a Chinese patient with nasopharyngeal carcinoma) was markedly different from that in B95-8 (a North American patient with infectious mononucleosis) and AG876 (a Western African patient with Burkitt lymphoma), suggesting that tumorigenic potential of LMP1 might be different based on geographic location (26) . In addition, polymorphism in the BamHI F region in the EBV genome, "f" variant, is more frequently observed in patients with nasopharyngeal carcinoma in Southern China compared with patients in North America (27) . One study showed that nasopharyngeal carcinoma with "f" variant demonstrated more frequent expression of phosphorylated STAT3, p53, BCL2, and higher Ki-67 proliferation rate compared with the F prototype, suggesting that genetic variation in EBV genome can contribute to the aggressiveness of tumor (28) . Taken together, different genetic variation in the EBV genome is seen in the different geographic regions and might explain differences in the different behavior of the disease. Although distinct clinical features were not observed, interesting pathologic and molecular features were observed in EBV þ DLBCL. Our data showed slightly higher frequency of the GCB type (39.3%) in EBV þ DLBCL compared with prior data (22%-32%; refs. 5, 8, 9, 11). Unlike others who used Hans or Choi algorithm for determining cell-of-origin, we used GEP as gold standard with immunohistochemistry as a complementary method. Of note, the Hans and Choi algorithms have reported 71% and 88% concordance and 96% and 89% concordance with GCB and ABC by GEP classification of DLBCL, respectively (16, 29 Combining clinical manifestation and morphology, reactive process was excluded in these 2 patients. Genetic aberrations involving BCL2, BCL6, MYC, MDM2, MDM4, and TP53 were infrequent (5%$11%), reinforcing the concept that the oncogenic effects of EBV might supplant the need for chromosomal or genetic abnormalities in lymphomagenesis (9) . Protein expression of the respective genes was not significantly different, except for less frequent expression of BCL6 in EBV þ DLBCLs. Although the underlying mechanism of decreased expression of BCL6 is unclear, an inverse correlation between BCL-6 and LMP1 was recognized previously (30) . A recent study showed that EBV microRNAs such as EBV-miR-BART9 and EBV-miR-BART17-5p could downregulate BCL6 expression in DLBCL (31) . Functional NF-kB protein exists as dimers composed of class I and class II molecules. Class I molecules, p50 and p52, contain nuclear localization regions without transcriptional action. Class II molecules, p65 (RelA), RelB, and cRel, have a transcription activation domain. Nuclear accumulation of p50/p65 or p50/c-Rel dimer is observed in the canonical pathway. In comparison, p52/relB dimers translocate to the nucleus in the alternative pathway. A significant increase of p50 expression in EBV þ DLBCL suggests that NFkB activation occurs via the canonical pathway. Considering that NF-kB activation is more common in ABC DLBCL (32), nuclear expression of canonical NF-kB components in EBV þ GCB DLBCL suggests EBV-induced canonical NF-kB activation in the tumor cells. However, single expression of LMP1 or EBNA2 did not show significant correlations with any of the studied NF-kB molecules. Our findings suggest that yet-unknown mechanism(s) induced by EBV might provide an additive effect on NF-kB activation. STAT3 is one of seven different members of the STAT family (STAT1, STAT2, STAT3, STAT4, STA5a, STAT5b, and STAT6) of transcription factors, and resides in an inactive form in the cytoplasm of nonstimulated cells. Activation of STAT3 is mediated by phosphorylation of a particular tyrosine residue (Tyr 705), which promotes dimerization through phosphotyrosine-SH2 domain interaction (33) . The dimerized STAT3 migrates to the nucleus and acts as a transcription factor. Constitutively active STAT3 can be seen in cancers in breast, lung, pancreas, and prostate (34) . Data showed that STAT3 can be activated by LMP1 (20, 35) . Moreover, EBNA2 was shown to be a transcriptional coactivator of STAT3 (36) . But no correlation between pSTAT3 and LMP1 or EBNA2 was observed in this study. Our findings might support that a synergistic effect of LMP1 and EBNA2 is required on STAT3 activation. pSTAT3 can physically interact with NF-kB dimer p50/p65 and the compound can recruit p300 histone acetyltransferase. Subsequently, p300 can acetylate activated (phosphorylated) p65 and increase its nuclear retention so as to prolong transcriptional activity of NF-kB (37 (9) . Although elucidation of these morphologic variants is of value to pathologists to facilitate recognition of EBV þ DLBCLs, in this study these morphologic variants did not have prognostic relevance. Our study has shown that EBV þ DLBCL is a genetically unique subset with increased canonical NF-kB and JAK/ STAT pathway activation, but EBV infection itself does not predict inferior outcome in Western developed countries if CD30 is not expressed. This is the first comprehensive study in this uniquely classified group of lymphoma patients from Western countries, providing a strong rationale of targeted therapy on the CD30 activation pathway for this subset of patients with DLBCL.
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